The Canadian Venous Thromboembolism Research Network (CanVECTOR) is a pan-Canadian, patient-oriented, Community Development Program centred on venous thromboembolism (VTE) related research, training, and knowledge translation.


To decrease the health, social and economic burden of VTE on affected individuals, their families, and on Canadians as a whole.


To create an enduring, pan-Canadian network of stakeholders, researchers, methodology experts, knowledge transfer experts, research trainees, clinical research professionals, industry partners, public agency partners, healthcare providers, and patient groups whose combined efforts to reduce VTE occurrence, improve VTE diagnosis and therapeutic management, improve the safety of anticoagulant delivery and enhance the quality of life of those impacted by VTE, both in Canada and globally.


  1. To build a critical mass of scientific expertise on a national scale by creating an enduring and sustainable network of partnerships, thus enriching Canada's continued international leadership in this field.

  2. To generate new knowledge by Canadian VTE researchers, with the input of patient partners, through clinical trials, translational research, and quality of care and effectiveness research. 

  3. To promote and facilitate the sharing of ideas, best practices, resources and platforms to build and sustain the infrastructure and transdisciplinary collaborations needed to more efficiently conduct high quality clinical trials that answer key questions impacting Canadians.

  4. To enhance our world-class VTE research capacity via a unique national research training, mentoring, and early career development program that will produce independent health researchers who lead patient-oriented and health services research in this field, and will recruit and train patient partners.

  5. To enhance our capacity for knowledge translation through a coordinated approach that will effectively translate research knowledge to maximize its impact on hospital and community-based practice, patients and their families, and patient-relevant health outcomes.




CanVECTOR is national in scope and has been developed in collaboration with academic, not-for-profit, and industry partners and stakeholders.

We are well-positioned to facilitate effective interactions and collaborations between the scientific community and various stakeholders (clinicians, decision-makers, industry, patients, and other knowledge users outside of the academic community). Led by co-Directors Dr. Susan Kahn and Dr. Grégoire Le Gal our membership includes leading senior, mid-level and early career clinical and basic science VTE researchers as well as experts in clinical trials, health services research, pharmacoepidemiology, biostatistics, health economics, biomarkers, systematic reviews, knowledge translation, nursing research, emergency department research, and patient engagement in research. Together, we have the necessary multidisciplinary expertise to meet our objectives.

Our work is organized into six platforms: three science platforms dedicated to VTE research (Clinical trials/shared research platforms; Translational/basic science; Quality of care and effectiveness research), and three foundational platforms for network activities that support all of our research (Training, mentoring, and early career development; Patient partners; Knowledge translation).

We are grateful to the Canadian Institutes of Health Research (CIHR) for initiating this funding opportunity.

Mission & Vision